LENZ Therapeutics paired a launch update with a leadership change. Third quarter product sales of VIZZ, its aceclidine eye drop for presbyopia, were $2.6 million on more than 38,000 paid prescriptions, increases of about 50 percent and 51 percent respectively over the second quarter, the company reported on October 28 in results furnished to the SEC. Total revenue was $3.4 million, including $0.8 million of license revenue, against $12.5 million a year earlier, when a licensing upfront payment inflated the comparison.
The channel detail shows where the growth is coming from. A telehealth prescribing option launched in July, offering online evaluation by independent licensed eye care providers with home delivery, contributed more than 50 percent of the incremental prescriptions in the quarter, and the company said more than 60 percent of its ePharmacy patients have bought more than one monthly pack. Momentum, it said, is continuing into the fourth quarter.
Against that growth, the company announced a strategic reorganization to prioritize consumer marketing, which it expects to reduce projected 2027 annual operating expenses by over 50 percent. Eef Schimmelpennink, who led the company for nearly six years through VIZZ’s development, approval and launch, will transition out of the president and chief executive roles on December 1, 2026 to devote more time to other pursuits, remaining as a strategic advisor. Chief financial officer Dan Chevallard will become interim president and chief executive.
Schimmelpennink said the reorganization focuses investment on initiatives that most effectively increase consumer awareness, access and adoption while improving capital efficiency. The tension in the announcement is plain: prescription volume is growing at about 50 percent a quarter from a very small base, and management has decided the fastest route to a larger base is consumer demand creation with a much smaller cost structure behind it, under new leadership.